UnknownNot Applicable

ARMA (Antireflux Mucosa Ablation) in Patients With Chronic Refractory Reflux Disease

Germany15 participantsStarted 2022-07-14

Plain-language summary

Pilot study of the possible clinical response to anti reflux mucosal ablation in patients with chronic refractory reflux disease

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * typical reflux symptoms more than 2x per week during PPI therapy more than 6 month * proof of gastro-esophageal reflux in pH metry oder pH/Impedance measurement Exclusion Criteria: * age \< 18 y * primary motility disorder of the esophagus * hiatal hernia \> 3 cm * Hill classification \> III * pregnancy * coagulation disorder * mandatory intake of oral anticoagulation drugs

What they're measuring

change of GERD-HRQL

Timeframe: Before and after 2 and 6 Month

Rate of major complications

Timeframe: day 1

Trial details

NCT IDNCT05425771

SponsorKlinikum Garmisch-Patenkirchen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-31

View on ClinicalTrials.gov More Gastro-esophageal Reflux trials